. 2003 Apr 29;88(9):1394–1399. doi: 10.1038/sj.bjc.6600890

Table 6. Risks of breast cancer for quartiles of hormone levels stratified for the time period between urine collection and diagnosis of breast cancer (<10 years; ⩾10 years).

		Time interval between urine collection and diagnosis of breast cancer
		<10 years			≥10 years
	Women in subcohort (n=382)	Breast cancer cases (n=184)	IRR^a	95% CI	Breast cancer cases (n=180)	IRR^a	95% CI
Oestrone
0.06–1.19 ng mg⁻¹	95	31	1.0	—	26	1.0	—
1.19–1.77 ng mg⁻¹	95	40	1.5	0.8–2.7	55	2.2	1.3–4.0
1.78–2.50 ng mg⁻¹	95	43	1.2	0.7–2.2	36	1.2	0.7–2.2
>2.50 ng mg⁻¹	95	69	2.6	1.5–4.6	63	2.3	1.3–4.0
P_trend				0.002			0.04

Oestradiol
0.08–0.34 ng mg⁻¹	95	38	1.0	—	39	1.0	—
0.34–0.49 ng mg⁻¹	96	34	0.9	0.5–1.6	45	1.3	0.7–2.2
0.49–0.77 ng mg⁻¹	96	55	1.4	0.8–2.4	46	1.3	0.8–2.3
>0.77 ng mg⁻¹	95	57	1.9	1.1–3.3	50	1.2	0.7–2.1
P_trend				0.007			0.45

Testosterone
0.03–1.85 ng mg⁻¹	95	39	1.0	—	41	1.0	—
1.86–2.71 ng mg⁻¹	96	51	1.2	0.7–2.2	37	1.0	0.6–1.7
2.72–4.16 ng mg⁻¹	96	55	1.4	0.8–2.5	57	1.5	0.9–2.6
>4.16 ng mg⁻¹	95	40	2.1	1.2–3.5	45	1.2	0.7–2.1
P_trend				0.009			0.24

5α-androstane-3α, 17β-diol
0.85–15.93 ng mg⁻¹	97	29	1.0	—	33	1.0	—
15.94–23.67 ng mg⁻¹	94	52	1.8	1.0–3.2	51	1.6	0.9–2.8
23.68–33.65 ng mg⁻¹	96	46	1.6	0.9–2.9	55	1.8	1.0–3.0
>33.65 ng mg⁻¹	95	57	2.3	1.3–4.1	40	1.3	0.8–2.4
P_trend				0.01			0.26
^aAdjusted for family history of breast cancer (yes/no). IRR, incidence rate ratio.